LEEM sees opportunity in French EU presidency

27 July 2008

The president of the French drug industry association, LEEM, Christian Lajoux, has outlined his hopes for the French presidency of the European Union in an interview with the physician's daily newspaper, Le Quotidien du Medecin. Drawing on President Nicolas Sarkozy's campaign to improve all aspects of Alzheimer's disease diagnosis and care in France, Mr Lajoux expressed his support for the coordination of research at a European level, including R&D partnerships between drugmakers, EU institutions and academic centers.

Mr Lajoux said: "only the drug manufacturers have, today, the sufficient scale and financial stability to ensure the development of the major innovative medicines. We are faced with a pathology for which, unfortunately, we do not dispose yet of the necessary therapeutic answers." The LEEM's president also noted that the national AD plan recently launched by Pres Sarkozy should be regarded as the precursor of a more powerful international effort to come (Marketletter July 14).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight